אפרקס 4000 ישראל - עברית - Ministry of Health

אפרקס 4000

j-c health care ltd - recombinant human erythropoietin - תמיסה להזרקה - recombinant human erythropoietin 4000 iu / 0.4 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 10000 ישראל - עברית - Ministry of Health

אפרקס 10000

j-c health care ltd - recombinant human erythropoietin - תמיסה להזרקה - recombinant human erythropoietin 10000 iu/ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 5000 ישראל - עברית - Ministry of Health

אפרקס 5000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 5000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 6000 ישראל - עברית - Ministry of Health

אפרקס 6000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 6000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 8000 ישראל - עברית - Ministry of Health

אפרקס 8000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 8000 iu / 0.8 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 40000 ישראל - עברית - Ministry of Health

אפרקס 40000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 40000 iu/ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 20000 ישראל - עברית - Ministry of Health

אפרקס 20000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 20000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat

אפרקס 30000 ישראל - עברית - Ministry of Health

אפרקס 30000

j-c health care ltd - erythropoietin human recombinant - תמיסה להזרקה - erythropoietin human recombinant 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) orb: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicate

גאמאגארד S/D אימונוגלובולין תוך ורידי 2.5 גר' ישראל - עברית - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 2.5 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

גאמאגארד S/D אימונוגלובולין תוך ורידי 5 גר' ישראל - עברית - Ministry of Health

גאמאגארד s/d אימונוגלובולין תוך ורידי 5 גר'

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation